16:24 EST Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline
- Datadog, Trade Desk upgraded: Wall Street’s top analyst calls
- Aardvark Therapeutics initiated with a Buy at BTIG
- Aardvark Therapeutics Hosts Investor Webinar on Drug Programs
- Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments